Novartis Ag (NVS) FCF Margin Growth (1y) (2010 - 2025)
Novartis Ag (NVS) FCF Margin Growth (1y) (2010 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Margin Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
1,396.00 |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-935.00 |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
1,326.00 |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
47.00 |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
1,043.00 |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
511.00 |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
1,008.00 |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
934.00 |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
1,484.00 |
| Date | Value |
|---|
| Jun 30, 2025 |
873.00 |
| Dec 31, 2024 |
42.00 |
| Jun 30, 2024 |
781.00 |
| Dec 31, 2023 |
-221,682.00 |
| Jun 30, 2023 |
184.00 |
| Dec 31, 2022 |
222,153.00 |
| Sep 30, 2022 |
-6,167.00 |
| Jun 30, 2022 |
-298.00 |
| Dec 31, 2021 |
-287,020.00 |
| Sep 30, 2021 |
3,808.00 |
| Jun 30, 2021 |
-264.00 |
| Jun 30, 2020 |
819.00 |
| Jun 30, 2019 |
-310.00 |
| Mar 31, 2019 |
-170.00 |
| Dec 31, 2018 |
19,259.00 |
| Jun 30, 2018 |
-6.00 |
| Dec 31, 2017 |
92.00 |
| Sep 30, 2017 |
-3,794.00 |
| Jun 30, 2017 |
-24,979.00 |
| Dec 31, 2016 |
122.00 |
